October 2, 2024 – Page 5

PharmAla to supply Harvard Medical School’s Maclean Hospital with LaNeo MDMA

Written by Customer Service on October 2, 2024. Posted in Public Companies.

TORONTO, Oct. 02, 2024 (GLOBE NEWSWIRE) — PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is proud to announce that it has been contracted as a supplier of MDMA to a clinical trial at Harvard’s Maclean Hospital, the largest neuroscientific and psychiatric private research hospital in the world. “As has recently been reported in the press, PharmAla has received numerous clinical trial inquiries and leads from key research organizations,” said Nicholas Kadysh, CEO, PharmAla Biotech. “We look forward to improving the lives of patients by providing high-quality MDMA to researchers in the US. We’re also exploring mechanisms to pre-position some...

Yes, Chef! AGS is Cookin’ Up A Feast of Epic Proportions at G2E 2024

Written by Customer Service on October 2, 2024. Posted in Public Companies.

Hot Slots, Pig Links, Pitmaster Progressives, and Top-Shelf Shufflers LAS VEGAS, Oct. 02, 2024 (GLOBE NEWSWIRE) — Global gaming supplier AGS (NYSE: AGS or “the Company”) will serve a full-course menu of delectable gaming experiences, including high-performing slot and iGaming content, cutting-edge cabinets, and revolutionary table game innovations at the 2024 Global Gaming Expo (“G2E”) in Las Vegas on October 8 to 10. Products for Every Space, Games for Every PalateAs AGS continues to evolve and secure its place among the top four slot suppliers in North America, its G2E showcase will highlight its ability to outfit nearly every corner of the casino floor and satisfy every player’s appetite. AGS will debut not one, not two, but three form factors from its new Spectra Plus cabinet line: Spectra SL49+™, Spectra SL49+™...

CERo Therapeutics, Inc. Names Al Kucharchuk Chief Financial Officer and Kristen Pierce Chief Development Officer

Written by Customer Service on October 2, 2024. Posted in Public Companies.

SOUTH SAN FRANCISCO, Calif, Oct. 02, 2024 (GLOBE NEWSWIRE) — CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo”), an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces key appointments to the Company’s management team to support recently named interim CEO, Chris Ehrlich. Andrew Albert “Al” Kucharchuk has been named Chief Financial Officer and Kristen Pierce, Ph.D., has been appointed Chief Development Officer. “I believe we have the team in place to successfully drive CERo forward into the clinic and to create the Company we have promised our shareholders. These new management team members are seasoned professionals with extensive experience in early drug development and the capital markets. I want to take this opportunity...

Navient to announce third quarter 2024 results, host earnings webcast Oct. 30

Written by Customer Service on October 2, 2024. Posted in Public Companies.

HERNDON, Va., Oct. 02, 2024 (GLOBE NEWSWIRE) — Navient (Nasdaq: NAVI) will host an audio webcast to review its 2024 third quarter financial results on Wednesday, Oct. 30, 2024, at 8:00 a.m. Eastern Time. The results are scheduled to be released the same day by 7:00 a.m. on Navient.com/investors. In addition to being available on the company’s investor website, the results will be filed with the SEC on a Form 8-K available at SEC.gov. The webcast and presentation slides also will be available on Navient.com/investors. Analysts and investors who wish to ask questions are requested to pre-register anytime ahead of the webcast or at least 15 minutes ahead of start time to receive their personal dial-in access details. Others who wish to join in listen-only mode do not need to pre-register and may simply visit the company’s investor...

American Rebel Holdings, Inc. Ships Re-Stocking Order from Kansas’ Standard Beverage for American Rebel Light Beer

Written by Customer Service on October 2, 2024. Posted in Public Companies.

American Rebel Holdings, Inc American Rebel Light Nashville, TN, Oct. 02, 2024 (GLOBE NEWSWIRE) — American Rebel Holdings, Inc. (NASDAQ: AREB) (“American Rebel” or the “Company”), the creator of American Rebel Beer (www.americanrebelbeer.com), and branded safes, personal security and self-defense products and apparel, announced their operating subsidiary American Rebel Beverages, LLC received a multi-pallet re-stocking order for 12-packs of 12oz cans from Kansas’ Standard Beverage. “Our relationship with Standard Beverage couldn’t be better and we are just getting started. We’re pleased to fulfill this reorder from a key distributor that participated in our initial pre-production run of American Rebel Light Lager,” said Andy Ross, Chief Executive Officer of American Rebel. “The reorder from Standard...

Notice on Convening an Extraordinary General Meeting of Shareholders of EPSO-G

Written by Customer Service on October 2, 2024. Posted in Public Companies.

In accordance with the initiative and decision of the Board of Energy Transmission and Exchange Group EPSO-G (legal entity code 302826889, registered address Laisvės pr. 10, Vilnius, Lithuania) the Extraordinary General Meeting of EPSO-G shareholders is convened. Reasons and purposes of convening the Meeting: election of members of the Audit Committee of EPSO-G. Agenda of the EPSO-G Extraordinary General Meeting of Shareholders: Regarding the election of members of the Audit Committee of EPSO-G. The EPSO-G group of companies consists of the holding company EPSO-G and its six direct subsidiaries Amber Grid, Baltpool, Energy cells, EPSO-G Invest, Litgrid and Tetas. EPSO-G and its Group companies also hold shares in GET Baltic, Baltic RCC OÜ and TSO Holding AS. The rights and obligations of the sole shareholder of EPSO-G are exercised by...

Mullen Announces Significant Revenue Increase and Reduction in Spending

Written by Customer Service on October 2, 2024. Posted in Earnings Releases And Operating Results.

For quarter ended Sept. 30, 2024, Company expects to report approximately $4.5 million in revenue compared to $65,235.00 reported in quarter ended June 30, 2024, an increase of 6791% compared to prior quarter Mullen reported a monthly cash burn (operating and investing cashflows) of $12.8 million for the quarter ended June 30, 2024, as compared to a monthly cash burn of $18.1 million for the quarter ended March 31, 2024, representing a decrease of 30% or $5.3 million per month. Company’s monthly cash burn for the quarter ended Sept. 30, 2024, is approximately $12.7 million per month The Company plans to continue to improve its cash burn with operating reductions throughout 2025 with the expectation to achieve breakeven on a cash basis by end of December 2025 BREA, Calif., Oct. 02, 2024 (GLOBE NEWSWIRE) — via IBN — Mullen...

Better Choice Company to Provide Update on SRx Health Transaction at the 2024 Sidoti Virtual Conference on November 13th & 14th

Written by Customer Service on October 2, 2024. Posted in Mergers And Acquisitions.

SRx Health Revenue for the fiscal year ending September 30, 2024 is expected to increase over 20% year-over-year to over CAD$200 million SRx Health management expects similar revenue growth year-over-year for fiscal 2025 Acquisition of SRx Health remains on-track TAMPA, Fla., Oct. 02, 2024 (GLOBE NEWSWIRE) — Better Choice Company (NYSE: BTTR) (“Better Choice” or “the Company”), a pet health and wellness company, today announced it will present at the Sidoti Virtual Conference on November 13-14, 2024. During the conference, management will provide an update on its ongoing acquisition of SRx Health. SRx Health Preliminary Revenue for FY2024 Ending September 30, 2024 and FY2025 Revenue Guidance: Fiscal Year 2024: SRx Health management expects revenue to increase over 20% year-over-year to over CAD$200 million. Fiscal Year 2025: SRx...

Medigene will Present at ASGCT 2024 and Host R&D Event

Written by Customer Service on October 2, 2024. Posted in Public Companies.

Planegg/Martinsried, October 2, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies for the treatment of cancer, will present a poster at the American Society of Gene & Cell Therapy (ASGCT) to be held October 16-17, 2024 in Philadelphia, PA in the US. In addition, the Company will host an R&D Event on Medigene’s optimal 3S (specific, sensitive, and safe) TCRs for TCR-guided precision immunotherapies on Thursday, October 10, 2024, at 4.30 pm CEST / 10:30 am ET. ASGCT 2024https://www.asgct.org/events/2024-advancing-gene-and-cell-therapies-for-cancerLocation: Wyndham Philadelphia Historic District, Philadelphia, PADate: October 16-17, 2024 The full abstract is now available on the ASGCT website: https://www.asgct.org/global/documents/abstracts/advancing-publication-v1.aspx Details...

GeoVax to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

Written by Customer Service on October 2, 2024. Posted in Public Companies.

ATLANTA, Ga., Oct. 02, 2024 (GLOBE NEWSWIRE) — GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, today announced that its Chairman & CEO, David Dodd, will participate in a panel discussion on innovative therapies for solid tumors at the 3rd Annual ROTH Healthcare Opportunities Conference taking place on October 9, 2024 in New York, NY. Senior GeoVax management will also host one-on-one meetings with registered attendees. Panel Details: Title: Innovative Therapies for Solid Tumors Presenter: David Dodd, Chairman & CEO Date/Time: October 9, 2024, 12:30 pm ET If you are interested in arranging a 1×1 meeting request with management, please contact your ROTH representative, or please contact the company directly at info@geovax.com. About...

Day: October 2, 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice